Table 2.
Antibiotic Susceptibility Profiles in Clinical Isolates of P. aeruginosa
| Antibiotics Resistance | β-lactamase genes | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total(%) | blaSHV(%) | blaTEM(%) | blaKPC(%) | blaIMP(%) | blaVIM(%) | blaGES(%) | |||||||||
| S | I | R | S | R | S | R | S | R | S | R | S | R | S | R | |
| Ceftazidime | 33(37.5%) | 16(18.1%) | 39(44.3%) | 4(12.1%) | 33(84.6%) | 0(0%) | 19(48.7%) | 0(0%) | 11(28.2%) | 0(0%) | 13(33.3%) | 0(0%) | 5(12.8%) | 0(0%) | 2(5.1%) |
| Doripenem | 46(52.2%) | 15(17.0%) | 27(30.6%) | 0(0%) | 25(92.5%) | 0(0%) | 20(74.0%) | 0(0%) | 12(44.4%) | 0(0%) | 12(44.4%) | 0(0%) | 5(18.5%) | 0(0%) | 2(7.4%) |
| Meropenem | 54(61.3%) | 13(14.7%) | 21(23.8%) | 1(1.8%) | 17(80.9%) | 0(0%) | 20(95.2%) | 0(0%) | 12(57.1%) | 0(0%) | 13(61.9%) | 0(0%) | 5(23.8%) | 0(0%) | 2(9.5%) |
| Imipenem | 40(45.4%) | 17(19.3%) | 31(35.2%) | 3(7.5%) | 25(80.6%) | 0(0%) | 20(64.5%) | 0(0%) | 12(38.7%) | 0(0%) | 13(41.9%) | 0(0%) | 5(16.1%) | 0(0%) | 2(6.4%) |
| Cefepime | 50(56.8%) | 11(12.5%) | 27(27.2%) | 1(2.0%) | 26(96.2%) | 0(0%) | 19(70.3%) | 0(0%) | 12(44.4%) | 0(0%) | 10(37.0%) | 0(0%) | 5(18.5%) | 0(0%) | 2(7.4%) |
| Gentamycin | 18(20.4%) | 11(12.5%) | 59(67.0%) | 0(0%) | 39(66.1%) | 1(5.5%) | 18(31.0%) | 0(0%) | 12(20.3%) | 0(0%) | 13(22.0%) | 0(0%) | 5(8.4%) | 0(0%) | 2(3.3%) |
| Ciprofloxacin | 12(13.6%) | 9(10.2%) | 67(76.1%) | 0(0%) | 39(58.2%) | 0(0%) | 20(29.8%) | 0(0%) | 12(17.9%) | 0(0%) | 13(19.4%) | 0(0%) | 5(7.4%) | 0(0%) | 2(2.9%) |
| Amikacin | 52(59.1%) | 17(19.3%) | 19(21.5%) | 0(0%) | 15(78.9%) | 1(1.9%) | 15(78.9%) | 0(0%) | 12(63.1%) | 0(0%) | 13(68.4%) | 0(0%) | 5(26.3%) | 0(0%) | 2(10.5%) |
| Norfloxacin | 50(56.8%) | 18(20.4%) | 20(22.7%) | 7(14.0%) | 11(55.0%) | 2(4.0%) | 13(65.0%) | 2(4.0%) | 9(45.0%) | 5(1.0%) | 7(35.0%) | 0(0%) | 2(10.0%) | 0(0%) | 2(1.0%) |
| Aztreonam | 67(76.1%) | 9(10.2%) | 12(13.6%) | 0(0%) | 11(91.6%) | 0(0%) | 11(91.6%) | 5(7.1%) | 5(41.6%) | 0(0%) | 11(91.6%) | 0(0%) | 5(41.6%) | 0(0%) | 2(16.6%) |
| Tobramycin | 68(77.2%) | 9(10.2%) | 11(12.5%) | 0(0%) | 11(100%) | 0(0%) | 11(100%) | 0(0%) | 11(100%) | 0(0%) | 11(100%) | 0(0%) | 3(27.2%) | 0(0%) | 2(18.1%) |
| Piperacillin | 48(54.5%) | 11(12.5%) | 29(28.4%) | 3(5.1%) | 25(86.2%) | 3(5.1%) | 14(48.2%) | 2(3.4%) | 6(20.6%) | 2(3.4%) | 8(27.5%) | 0(0%) | 2(6.8%) | 0(0%) | 2(6.8%) |
| Piperacillin/tazobactam | 48(54.4%) | 16(18.1%) | 24(27.2%) | 2(4.1%) | 19(79.1%) | 3(6.2%) | 11(45.8%) | 3(6.2%) | 7(29.1%) | 3(6.2%) | 6(25.0%) | 0(0%) | 2(8.3%) | 0(0%) | 2(8.3%) |
| MDR | 37(22.4%) | 35(94.5%) | 17(45.9%) | 12(32.4%) | 12(32.4%) | 5(13.5%) | 2(5.4%) | ||||||||
| β-lactamase-producer strain | |||||||||||||||
| class A β-lactamases (ESBL) | 43(22.4%) | 39(90.6%) | 20(46.5%) | 10(23.2%) | 8(18.6%) | 5(11.6%) | 2(4.6%) | ||||||||
| class B β-lactamases (MBL) | 7(22.4%) | 5(71.4%) | 5(71.4%) | 7(100%) | 7(100%) | 5(71.4%) | 2(28.5%) | ||||||||
| class D β-lactamases (KPC) | 11 (12.5%) (Hodge test)19 (21.5%) (Carba-NP) | 11 (100%)17 (89.7%) | 10 (90.9%)14 (73.6%) | 11 (100%)12 (63.1%) | 11 (100%)9 (47.3%) | 5 (45.4%)4 (21.0%) | 2 (18.1%)2 (10.5%) | ||||||||
| Clinical isolates | |||||||||||||||
| Wound | 26(29.5%) | 17(65.3%) | 14(53.8%) | 8(30.6%) | 11(42.3%) | 11(42.3%) | 2(7.6%) | ||||||||
| Blood | 19(21.5%) | 13(68.4%) | 5(26.3%) | 2(10.5%) | 2(10.5%) | 2(10.5%) | 0(0%) | ||||||||
| Urine | 10(11.3%) | 5(50.0%) | 1(1.0%) | 1(1.0%) | 1(0%) | 1(0%) | 0(0%) | ||||||||
| Catheter | 11(12.5%) | 3(27.2%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) | ||||||||
| Other case | 22(25%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) | ||||||||